Compare AORT & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AORT | MDXG |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.0B |
| IPO Year | 1993 | N/A |
| Metric | AORT | MDXG |
|---|---|---|
| Price | $44.94 | $7.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $49.36 | $12.00 |
| AVG Volume (30 Days) | 356.3K | ★ 774.9K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $422,646,000.00 | $393,442,000.00 |
| Revenue This Year | $15.97 | $19.13 |
| Revenue Next Year | $10.96 | $2.11 |
| P/E Ratio | ★ N/A | $26.73 |
| Revenue Growth | 9.81 | ★ 14.77 |
| 52 Week Low | $21.97 | $5.79 |
| 52 Week High | $48.04 | $9.71 |
| Indicator | AORT | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 56.44 |
| Support Level | $42.68 | $6.62 |
| Resistance Level | $46.02 | $7.06 |
| Average True Range (ATR) | 1.35 | 0.23 |
| MACD | -0.18 | 0.05 |
| Stochastic Oscillator | 53.39 | 91.11 |
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.